Karyopharm Therapeutics (KPTI) Proxy Filing summary

Executive summary

• Special meeting scheduled for February 18, 2026, to be held virtually for shareholder convenience and broader participation.

• Main agenda: vote on increasing authorized capital stock and common stock, and potential adjournment if more votes are needed.

• Board recommends approval of both proposals to support future capital raising and strategic flexibility.

• Forward-looking statements highlight risks and uncertainties, especially regarding future capital needs and business plans.

Voting matters and shareholder proposals

• Proposal 1: Amend Restated Certificate of Incorporation to increase authorized capital stock from 58,333,333 to 111,000,000 and common stock from 53,333,333 to 106,000,000.

• Proposal 2: Adjournment proposal to allow more time for proxy solicitation if needed.

• Board recommends voting FOR both proposals.

• Only stockholders of record as of December 29, 2025, are eligible to vote; each share equals one vote.

• Stockholder proposals for the 2026 annual meeting must be received by December 15, 2025, for inclusion.

Board of directors and corporate governance

• Board retains discretion to abandon the authorized shares amendment even if approved by shareholders.

• No other business will be transacted at the special meeting beyond the stated proposals.